Serum Exosomes Expressing CD9, CD63 and HER2 From Breast-Cancer Patients Decreased After Surgery of the Primary Tumor: A Potential Biomarker of Tumor Burden
Serum exosomes expressing CD9, CD63 and HER2 are candidate biomarkers of tumor burden in HER2-positive breast-cancer patients.
Authors
- Marina KUNIYASU
- Sachiko Inubushi (ORCID: https://orcid.org/0000-0003-0541-4942)
- Robert M. Hoffman (ORCID: https://orcid.org/0000-0002-0049-0041)
- YUJI YAMASHITA
- Tomonari Kunihisa (ORCID: https://orcid.org/0000-0003-2805-6746)
- Sachiko Mizumoto
- Mayuko Miki
- Mayuko Yamamoto
- Motoi Baba
- Hirokazu Tanino (ORCID: https://orcid.org/0000-0002-6704-3641)
- SHOTARO INOUE
Institutions
- Wakayama Medical University (JP)
- University of California San Diego (US)
- AntiCancer (United States) (US)
- Kobe University (JP)
Publication Details
- Journal
- Cancer Genomics & Proteomics
- Published
- 2024-10-28
- DOI
- https://doi.org/10.21873/cgp.20474
- Citations
- 13
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Japan Society for the Promotion of Science